Posts

Showing posts from February, 2022

Is The Begetting of Triplets Associated With The Developing of 3 Breast Primaries?

Image
  Cancer Therapy & Oncology- Juniper Publishers                                                      Abstract A Birmingham (UK) group considered in 1980 that the establishment of a Histopathology data pool encourages epidemiologic analysis. Consequently, the senior author (WIBO) had such an advantageous opportunity. Interestingly, the junior author (GEN), working in a near Surgical Outpatient Clinic, was consulted by a gravid 5, para 8, patient, i.e., one twin and a set of triplets. Moreover, she also developed 3 breast carcinomas. Therefore, this paper is documented in order to stimulate worldwide interest in this peculiar combination. Is it only happenstance or an explicable natural event?. Keywords:  Breast, triple cancer, pregnancy, triplets, Igbos, epidemiology Introduction The breast has for centuries been the medical man’s talking point. Thus, as the physician/historian, Henry Sigerist, summed it up, "it was chiefly cancer of the breast that attracted the physician’s at

Drivers of Precision Medicine: Liquid Biopsy and Next-Generation Sequencing

Image
Cancer Therapy & Oncology- Juniper Publishers                                                      Abbreviations cfDNA: Cell-Free DNA; NGS: Next-Generation Sequencing; WGS: Whole Genome Sequencing; WES: Whole Exome Sequencing; GH: Guardant Health; CT: Circulogene Theranostics Editorial Targeted therapy specifically aims at tumor genetic alterations s the hallmark of precision medicine. Companion diagnostic testing utilized to determine the presence or absence of certain oncogenic mutations prior to targeted treatment under the current medical guidelines will enable improved clinical outcome, and thus serves as a vital component for precision medicine. Standard clinical practice to assess genetic mutations in cancer patients has historically been through direct sampling of tumor tissue with biopsy or surgical resection. Unfortunately, tissue biopsy is one-time single-site sampling, painful, costly, and can miss the dynamics of tumor clonally evolution during disease progression. The